ResMed Inc (RMD)

Cash ratio

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Cash and cash equivalents US$ in thousands 1,209,450 932,711 521,944 426,361 238,361 237,910 210,247 209,100 227,891 227,894 253,199 207,163 273,710 201,769 194,476 276,149 295,278 230,635 255,865 421,414
Short-term investments US$ in thousands — 12,131 — — 12,026 21,537 7,617 11,821 12,423 12,115 4,980 — 9,167 17,842 19,566 33,138 — 24,011 — 2,020
Total current liabilities US$ in thousands 1,019,120 940,516 851,960 904,079 910,655 773,030 764,073 770,802 758,533 761,691 732,714 692,659 689,299 667,265 621,064 624,158 911,766 876,541 577,335 590,853
Cash ratio 1.19 1.00 0.61 0.47 0.27 0.34 0.29 0.29 0.32 0.32 0.35 0.30 0.41 0.33 0.34 0.50 0.32 0.29 0.44 0.72

June 30, 2025 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($1,209,450K + $—K) ÷ $1,019,120K
= 1.19

The cash ratio of ResMed Inc., as derived from the provided data, demonstrates notable fluctuations over the analyzed period. Starting at 0.72 as of September 30, 2020, the ratio shows a declining trend through subsequent quarters, reaching a low of 0.27 by June 30, 2024. Notable dips are observed during the 2021 fiscal year, with the ratio decreasing from 0.50 in September 2021 to around 0.33–0.35 in subsequent quarters. This suggests a reduction in the company's cash holdings relative to its current liabilities during this period.

Subsequent periods display some recovery; the ratio increases from 0.29 in September 2023 to 0.47 in September 2024 and further to 0.61 by December 2024. The most recent data indicating March 31, 2025, reports a significant rise to 1.00, with June 30, 2025, reaching 1.19. These figures indicate an improved liquidity position, with the company's cash holdings now exceeding its current liabilities.

Overall, the pattern suggests that ResMed Inc. experienced a substantial decline in its cash ratio from 2020 through mid-2024, reflecting a period of reduced cash liquidity relative to current liabilities. However, the subsequent period indicates a robust strengthening of liquidity, culminating in a cash ratio exceeding 1.0 by March 2025. This trend may imply strategic management adjustments, improved cash generation, or changes in the company's current liabilities structure, leading to enhanced short-term liquidity positioning at the most recent reporting dates.